Evidence map›Paper›PMID 19648253›Full record

ArticleAmerican journal of physiology. Heart and circulatory physiology2009

Sphingosine 1-phosphate is an important endogenous cardioprotectant released by ischemic pre- and postconditioning.

Donald A Vessey, Luyi Li, Norman Honbo, Joel S Karliner

Open access · greenAbstract read
In one paragraph

Article in American journal of physiology. Heart and circulatory physiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 81 citations in OpenAlex.

  1. Review
  2. Promoting Resiliency to Stress in the Vascular Endothelium.Basic & clinical pharmacology & toxicology · 2025
    Review
  3. Article
  4. Potential Drug Targets for Ceramide Metabolism in Cardiovascular Disease.Journal of cardiovascular development and disease · 2022
    Review
  5. Article
  6. Sphingolipid metabolism and signaling in cardiovascular diseases.Frontiers in cardiovascular medicine · 2022
    Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. P2 Receptors in Cardiac Myocyte Pathophysiology and Mechanotransduction.International journal of molecular sciences · 2020
    Review
  12. Review
  13. Sphingolipid Mediators of Myocardial Pathology.Journal of lipid and atherosclerosis · 2020
    Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Selective coupling of the S1PJournal of molecular and cellular cardiology · 2017
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Donald A VesseyLiver Study Unit, Department of Veterans Affairs Medical Center, San Francisco, California 94121, USA. donald.vessey@va.gov
Luyi Li
Norman Honbo
Joel S Karliner
Unité de Nutrition Humaine · FRSan Francisco VA Medical Center · USUniversity of California, San Francisco · US

Funding

Mechanisms of Cardioprotection in Ischemia and FailureP01HL068738 · NHLBI · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI KARLINER, JOEL SAMUEL · 2002 to 2006
$8.6M
Sphingosine 1-phosphate and cardioprotectionR01HL090606 · NHLBI · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI KARLINER, JOEL SAMUEL · 2009 to 2012
$1.5M
NHLBI NIH HHS P01 HL068738NHLBI NIH HHS P01HL068738NHLBI NIH HHS R01 HL090606NHLBI NIH HHS R01HL090606
6 · The paper itself

Abstract

Exogenous sphingosine 1-phosphate (S1P) is an effective cardioprotectant against ischemic injury. We have investigated the hypothesis that S1P is also an important endogenous cardioprotectant released during both ischemic preconditioning (IPC) and ischemic postconditioning (IPOST). IPC of ex vivo rat hearts was instituted by two cycles of 3 min ischemia-5 min reperfusion prior to 40 min of index ischemia and then 40 min of reperfusion. IPC resulted in 70% recovery of left ventricular developed pressure (LVDP) upon reperfusion and a small infarct size (10%). VPC23019 (VPC), a specific antagonist of S1P(1 and 3) G protein-coupled receptors (GPCRs), when present during preconditioning blocked protection afforded by two cycles of IPC. VPC also blocked preconditioning of isolated rat cardiac myocytes subjected to hypoxia-reoxygenation injury. Increased release of S1P from myocytes in response to IPC was also demonstrated. These data indicate that S1P is released from myocytes in response to IPC and protects by binding to S1P GPCRs. In the ex vivo heart, if a third cycle of IPC was added to increase release of endogenous mediators, then the need for any individual mediator (e.g., S1P) was diminished and VPC had little effect. The adenosine antagonist 8-(p-sulfophenyl)-theophylline (8-SPT) likewise inhibited protection by two cycles but not three cycles of IPC, but VPC plus 8-SPT inhibited protection by three cycles of IPC. Similar to IPC, IPOST induced by four postindex ischemia cycles of 15 s reperfusion-15 s ischemia resulted in 66% recovery of LVDP and a 7% infarct size. When VPC was present during postconditioning and reperfusion, LVDP only recovered by 26% and the infarct size increased to 27%. Adding an additional cycle of IPOST reduced the inhibitory effect of VPC and 8-SPT individually, but not their combined effect. These studies reveal that S1P is an important mediator of both IPC and IPOST that is released along with adenosine during each cycle of IPC or IPOST.

Indexed as

Ischemic Preconditioning, MyocardialVentricular Function, LeftAdenosineAnimalsAnimals, NewbornCells, CulturedIn Vitro TechniquesLysophospholipidsMyocardial InfarctionMyocardial Reperfusion InjuryMyocardiumMyocytes, CardiacPerfusionPurinergic P1 Receptor AntagonistsRatsRats, Sprague-Dawley8-(4-sulfophenyl)theophyllineAdenosineLysophospholipidsPurinergic P1 Receptor AntagonistsReceptors, LysosphingolipidReceptors, Purinergic P1Sphingosinesphingosine 1-phosphateTheophylline

Identifiers

PMID19648253
PMCPMC2770755
OpenAlexW2063898672

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.